Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · Real-Time Price · USD

15.53

+0.18 (1.17%)

At close: Aug 21, 2026, 4:00 PM EDT

15.47

-0.06 (-0.42%)

After-hours: Aug 21, 2026, 7:30 PM EDT

Lyell Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	72.99	60.18	105.6	145.65	123.55	293.83
Short-Term Investments	131.12	187.04	264.93	400.58	516.6	320.97
Cash & Short-Term Investments	204.1	247.22	370.53	546.22	640.15	614.79
Cash Growth	-26.26%	-33.28%	-32.17%	-14.67%	4.13%	0.36%
Prepaid Expenses	9.44	13.72	9.07	8.46	11.14	11.49
Total Current Assets	213.54	260.94	379.59	554.69	651.3	626.29
Property, Plant & Equipment	47.29	53.64	72.94	142.32	166.27	166.64
Long-Term Investments	42.9	19	32.01	48.51	115.04	330.53
Other Long-Term Assets	7.43	6.47	6.31	4.52	4.96	3.95
Total Assets	311.15	340.05	490.86	750.03	937.56	1,127

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	3.88	2.89	5.37	4.82	3.92	3.21
Accrued Expenses	25.82	20.94	29.37	20.36	21.14	22.36
Current Portion of Leases	9.66	9.07	7.97	6.27	4.53	1.17
Current Unearned Revenue	-	2.54	0.48	-	-	4.99
Other Current Liabilities	0.5	13.97	10.6	3.07	7.44	15.01
Total Current Liabilities	39.87	49.41	53.79	34.52	37.03	46.74
Long-Term Leases	36.93	41.92	50.99	56.89	63.17	66.65
Long-Term Unearned Revenue	-	-	-	-	-	79.67
Other Long-Term Liabilities	0.54	0.52	3.25	3.66	4.11	4.57
Total Liabilities	77.34	91.85	108.04	95.08	104.31	197.62

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0	0	0	0.03	0.03	0.02
Additional Paid-In Capital	1,922	1,868	1,728	1,657	1,608	1,516
Retained Earnings	-1,688	-1,620	-1,345	-1,002	-767.48	-584.36
Comprehensive Income & Other	-0.16	0.24	0.29	-0.09	-7.6	-1.62
Total Common Equity	233.82	248.2	382.82	654.95	833.25	929.79
Shareholders' Equity	233.82	248.2	382.82	654.95	833.25	929.79
Total Liabilities & Equity	311.15	340.05	490.86	750.03	937.56	1,127

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	46.6	50.99	58.97	63.17	67.7	67.82
Net Cash (Debt)	181.4	196.23	324.57	499.56	642.57	830.51
Net Cash Growth	-24.96%	-39.54%	-35.03%	-22.25%	-22.63%	30.16%
Net Cash Per Share	8.63	11.48	24.83	39.81	52.01	122.21
Filing Date Shares Outstanding	24.51	23.31	14.76	12.7	12.48	12.14
Total Common Shares Outstanding	23.4	21.25	14.74	12.7	12.48	12.14
Working Capital	173.67	211.53	325.81	520.17	614.27	579.55
Book Value Per Share	9.99	11.68	25.97	51.58	66.78	76.61
Tangible Book Value	233.82	248.2	382.82	654.95	833.25	929.79
Tangible Book Value Per Share	9.99	11.68	25.97	51.58	66.78	76.61
Machinery	-	28.86	39.03	35.85	34.33	29.03
Construction In Progress	-	0.45	0.24	0.13	4.15	10.58
Leasehold Improvements	-	79.74	79.61	118.32	116.93	95

SEC Filings: 10-K · 10-Q